AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30760195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ω-3 fatty acids and nano-curcumin
Number of subjects: 74
Study 30760195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 28187335 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic dose reduction
Number of subjects: 16
Study 26711204 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIA with dexmedetomidine and sufentanil (Group D)
Number of subjects: 152
Study 26711204 — intervention group
Group type: COMPARATOR
Intervention: PCIA with sufentanil (Group S)
Number of subjects: 152
Study 23896681 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) treatment
Number of subjects: 1434
Study 23896681 — intervention group
Group type: COMPARATOR
Intervention: HIV replication (untreated state)
Number of subjects: 1434
Study 21966218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Education plus Resistance Training (DERT)
Number of subjects: 27
Study 21966218 — intervention group
Group type: COMPARATOR
Intervention: Dietary Education (DE)
Number of subjects: 27
Study 18253118 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 60 mg m(‐2) on days 1 and 8 and cisplatin 60 mg m(‐2) on day 1 with etoposide 50 mg m(‐2) on days 1‐3 (n=55)
Number of subjects: 109
Study 18253118 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan 60 mg m(‐2) on days 1 and 8 and cisplatin 60 mg m(‐2) on day 1 without etoposide (n=54)
Number of subjects: 109
Study 16523797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 16523797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14561117 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group
Number of subjects: 0
Study 14561117 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 11206019 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of enoxaparin
Number of subjects: 1102
Study 11206019 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of enoxaparin
Number of subjects: 1102
Study 11206019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1102
Study 8969334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive management
Number of subjects: 0
Study 1467096 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. morphine 0.15 mg kg‐1 as required
Number of subjects: 40
Study 1467096 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with i.v. morphine 1 mg and a 5-min lock out time
Number of subjects: 40
Study 1467096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 6372988 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 189
Study 6372988 — intervention group
Group type: COMPARATOR
Intervention: Nonsplenectomy
Number of subjects: 189
Study 30245169 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen suppression combined with elective nodal and dose-escalated radiation therapy (DE-EBRT)
Number of subjects: 398
Study 30245169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose-rate prostate brachytherapy boost (LDR-PB)
Number of subjects: 398
Study 30245169 — intervention group
Group type: COMPARATOR
Intervention: Standard arm with 12 months of androgen deprivation therapy and pelvic EBRT
Number of subjects: 398
Study 27322002 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic pump Adalat® XL 60 mg
Number of subjects: 0
Study 27322002 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-type Adalat® Eins 30 mg
Number of subjects: 0
Study 27322002 — intervention group
Group type: COMPARATOR
Intervention: Quality control dissolution methods
Number of subjects: 0
Study 27322002 — intervention group
Group type: EXPERIMENTAL
Intervention: Level II biorelevant media
Number of subjects: 0
Study 24607075 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program (progressive muscle relaxation combined with diaphragmatic breathing) for 8 weeks
Number of subjects: 44
Study 24607075 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 22781352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside analogue treatment
Number of subjects: 23
Study 22781352 — intervention group
Group type: COMPARATOR
Intervention: Alpha interferon treatment
Number of subjects: 23
Study 22781352 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Nucleoside analogue and Alpha interferon)
Number of subjects: 23
Study 20053951 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG‐BFB treatment
Number of subjects: 20
Study 20053951 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional therapy)
Number of subjects: 20
Study 18725513 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day of conjugated equine estrogen plus 2.5 mg/day of medroxyprogesterone acetate
Number of subjects: 16608
Study 18725513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study 16209674 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (vodka, 50% alcohol, 1 mL/kg body weight with 500 mL of orange and cranberry juice)
Number of subjects: 10
Study 16209674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mL of orange and cranberry juice)
Number of subjects: 10
Study 12645831 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gemifloxacin (320 mg once daily, 5 days)
Number of subjects: 274
Study 12645831 — intervention group
Group type: COMPARATOR
Intervention: Sequential intravenous (i.v.) ceftriaxone (1 g once daily, maximum 3 days) followed by oral cefuroxime axetil (500 mg twice daily, maximum 7 days)
Number of subjects: 274
Study 12645831 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gemifloxacin
Number of subjects: 274
Study 12645831 — intervention group
Group type: COMPARATOR
Intervention: Sequential i.v. ceftriaxone/oral cefuroxime
Number of subjects: 274
Study 12645831 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 274
Study 10859284 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 4039
Study 10859284 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 4039
Study 10859284 — intervention group
Group type: COMPARATOR
Intervention: PTCA (randomized trial)
Number of subjects: 4039
Study 10859284 — intervention group
Group type: COMPARATOR
Intervention: CABG (randomized trial)
Number of subjects: 4039
Study 10859284 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA (registry)
Number of subjects: 4039
Study 10859284 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (registry)
Number of subjects: 4039
Study 10859284 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA and CABG (treated diabetics)
Number of subjects: 4039
Study 8879372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg twice a day
Number of subjects: 111
Study 8879372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 1672001 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term hospital stay (about 1 week)
Number of subjects: 61
Study 1672001 — intervention group
Group type: COMPARATOR
Intervention: Long-term hospital stay (about 4 weeks)
Number of subjects: 61
Study 1672001 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (short-term and long-term)
Number of subjects: 61
Study 6436523 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide-based, low osmolality elemental diet
Number of subjects: 12
Study 6436523 — intervention group
Group type: COMPARATOR
Intervention: Polymeric diet
Number of subjects: 12
Study 30844989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC) at 250 mm Hg
Number of subjects: 10
Study 30844989 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 10 mm Hg
Number of subjects: 10
Study 28592620 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebananib 10 mg/kg plus sorafenib 400 mg orally twice daily
Number of subjects: 30
Study 28592620 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebananib 15 mg/kg plus sorafenib 400 mg orally twice daily
Number of subjects: 30
Study 28592620 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib historical control
Number of subjects: 30
Study 25689289 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% BAC
Number of subjects: 24
Study 25689289 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08% BAC
Number of subjects: 24
Study 25689289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25689289 — intervention group
Group type: EXPERIMENTAL
Intervention: All BAC conditions
Number of subjects: 24
Study 23344124 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep extubation
Number of subjects: 100
Study 23344124 — intervention group
Group type: COMPARATOR
Intervention: Awake extubation
Number of subjects: 100
Study 21943112 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in the ADIPOR2 locus (rs10848554, rs11061937, rs1058322, rs16928751)
Number of subjects: 484
Study 21943112 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for the rare minor alleles of rs11061946 and rs11061973
Number of subjects: 484
Study 21943112 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expression levels of ADIPOR2
Number of subjects: 484
Study 19480732 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya isoflavones (116 mg isoflavone equivalents/d: 68 mg daidzein, 12 mg genistein, 36 mg glycitin)
Number of subjects: 34
Study 19480732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16580393 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 46
Study 16580393 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 46
Study 12616111 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 101
Study 12616111 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux surgery
Number of subjects: 101
Study 11340682 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn CF screening by heel-prick immunoreactive trypsin (IRT) measurement
Number of subjects: 464586
Study 11340682 — intervention group
Group type: COMPARATOR
Intervention: Diagnosis by clinical presentation (unscreened group)
Number of subjects: 464586
Study 9093424 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine-primaquine
Number of subjects: 66
Study 9093424 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine-primaquine
Number of subjects: 66
Study 8181192 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg daily for 1 week)
Number of subjects: 6
Study 8181192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 6
Study 3318598 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg 4 times a day for 3 days)
Number of subjects: 11
Study 3318598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31468664 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 14
Study 31468664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28991749 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed consensus gene selection criteria using Distributed GPU implementation
Number of subjects: 0
Study 28991749 — intervention group
Group type: COMPARATOR
Intervention: Conventional SVM-RFE
Number of subjects: 0
Study 28991749 — intervention group
Group type: COMPARATOR
Intervention: t-test
Number of subjects: 0
Study 26653329 — intervention group
Group type: EXPERIMENTAL
Intervention: iEat foods (foods with good appearance and greater softness)
Number of subjects: 0
Study 26653329 — intervention group
Group type: COMPARATOR
Intervention: Blender-processed foods
Number of subjects: 0
Study 24714538 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophy-type resistance training (3 sets of 10 RM with 90 seconds rest)
Number of subjects: 17
Study 24714538 — intervention group
Group type: COMPARATOR
Intervention: Strength-type resistance training (7 sets of 3 RM with 3 minutes rest)
Number of subjects: 17
Study 23929523 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive exercise training (n = 12)
Number of subjects: 24
Study 23929523 — intervention group
Group type: COMPARATOR
Intervention: Control exercise with no resistance (n = 12)
Number of subjects: 24
Study 21262889 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia screening among women 14 to 15 years of age
Number of subjects: 0
Study 21262889 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia screening among women 20 to 21 years of age
Number of subjects: 0
Study 21262889 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia screening among women 22 to 23 years of age
Number of subjects: 0
Study 21262889 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia screening among women 24 to 25 years of age
Number of subjects: 0
Study 21262889 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia screening among Black women
Number of subjects: 0
Study 21262889 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia screening among Hispanic women
Number of subjects: 0
Study 21262889 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia screening among women with public insurance
Number of subjects: 0
Study 21262889 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia screening among women with public pending insurance
Number of subjects: 0
Study 18355218 — intervention group
Group type: EXPERIMENTAL
Intervention: Right from the Start (RFTS)
Number of subjects: 76
Study 18355218 — intervention group
Group type: COMPARATOR
Intervention: Home visiting (treatment as usual)
Number of subjects: 76
Study 16931678 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg every 12 h for 72 h postoperatively
Number of subjects: 48
Study 16931678 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 12 h for 72 h postoperatively
Number of subjects: 48
Study 16931678 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 48
Study 16931678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12788192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 5 mg
Number of subjects: 249
Study 12788192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 11119400 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 0
Study 11119400 — intervention group
Group type: COMPARATOR
Intervention: Routine antibiotic treatment
Number of subjects: 0
Study 11119400 — intervention group
Group type: COMPARATOR
Intervention: Combination of patient and physician education
Number of subjects: 0
Study 9383115 — intervention group
Group type: COMPARATOR
Intervention: 30 min of cycling exercise at 60% VO2max
Number of subjects: 12
Study 9383115 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test
Number of subjects: 12
Study 2885853 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole suspension (5 ml, 1 mg/ml) once daily
Number of subjects: 65
Study 2885853 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine suspension (5 ml, 6 mg/ml) twice daily
Number of subjects: 65
Study 30358153 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and additional (whey) protein intake (PRO)
Number of subjects: 76
Study 30358153 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care, additional protein intake, and supervised strength training for 18 weeks (PRO+EX)
Number of subjects: 76
Study 30358153 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CON)
Number of subjects: 76
Study 30358153 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care, additional protein intake, and supervised strength training (PRO+EX)
Number of subjects: 76
Study 26723801 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care intervention with automated alert messages to physicians and staff
Number of subjects: 313
Study 26723801 — intervention group
Group type: COMPARATOR
Intervention: Matched discharges from the previous 1.5 years (Control)
Number of subjects: 313
Study 23410501 — intervention group
Group type: EXPERIMENTAL
Intervention: Back massage therapy (20 minutes session for 5 consecutive days)
Number of subjects: 60
Study 23410501 — intervention group
Group type: COMPARATOR
Intervention: Control group (received the same care without back massage)
Number of subjects: 60
Study 22236804 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (n = 14)
Number of subjects: 30
Study 22236804 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (n = 16)
Number of subjects: 30
Study 20438327 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS with honey
Number of subjects: 100
Study 20438327 — intervention group
Group type: COMPARATOR
Intervention: ORS (control)
Number of subjects: 100
Study 19252457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressings with Safetac adhesive technology
Number of subjects: 0
Study 16551151 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire-plus-implementation intention
Number of subjects: 554
Study 16551151 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire-only
Number of subjects: 554
Study 13130320 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 55
Study 13130320 — intervention group
Group type: COMPARATOR
Intervention: Oral diet (OD)
Number of subjects: 55
Study 11073745 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (3 mg/kg/d)
Number of subjects: 243
Study 11073745 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (5 mg/kg/d)
Number of subjects: 243
Study 11073745 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B lipid complex (ABLC)
Number of subjects: 243
Study 9361912 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1.2 grams daily for 3 days)
Number of subjects: 114
Study 9361912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight dextran (for 3 days)
Number of subjects: 114
Study 9361912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 114
Study 1312797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (750 mg/day)
Number of subjects: 11
Study 1312797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2996726 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5-10 mg twice a day)
Number of subjects: 23
Study 2996726 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40-80 mg 4 times a day)
Number of subjects: 23
Study 31343376 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO‐L (local administration)
Number of subjects: 70
Study 31343376 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO‐IP (intraperitoneal administration)
Number of subjects: 70
Study 31343376 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 31343376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham group
Number of subjects: 70
Study 30942032 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied during the operation and within 1 month after the operation, once every other day at specific acupuncture points (Hegu, Qihai, Zhongwan, Pishu, Shenshu).
Number of subjects: 80
Study 30942032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electroacupuncture treatment).
Number of subjects: 80
Study 28846143 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐mm‐tip catheter
Number of subjects: 150
Study 28846143 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5‐mm open irrigation‐tip catheter
Number of subjects: 150
Study 28846143 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5‐mm open irrigation porous‐tip catheter
Number of subjects: 150
Study 25744224 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (booster dose)
Number of subjects: 100
Study 25744224 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-CRM (primary dose)
Number of subjects: 100
Study 24159565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 87
Study 24159565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 21512577 — intervention group
Group type: EXPERIMENTAL
Intervention: Two double doses of influenza vaccine over 28 days
Number of subjects: 298
Study 21512577 — intervention group
Group type: COMPARATOR
Intervention: Two standard doses of influenza vaccine over 28 days
Number of subjects: 298
Study 21512577 — intervention group
Group type: COMPARATOR
Intervention: Single standard dose of influenza vaccine
Number of subjects: 298
Study 19192876 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPO (Minimal Invasive Plating Osteosynthesis)
Number of subjects: 40
Study 19192876 — intervention group
Group type: COMPARATOR
Intervention: ORPO (Open Reduction and Plating Osteosynthesis)
Number of subjects: 40
Study 16776702 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs (patients with sleep-related migraine)
Number of subjects: 10
Study 16776702 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for age and sex)
Number of subjects: 10
Study 14872039 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone (40 mg/kg as first line)
Number of subjects: 22
Study 14872039 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 22
Study 14872039 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (as second line)
Number of subjects: 22
Study 11127487 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day moxifloxacin 400 mg once daily
Number of subjects: 567
Study 11127487 — intervention group
Group type: COMPARATOR
Intervention: 5-day azithromycin (500 mg qd x 1, then 250 mg qd x 4)
Number of subjects: 567
Study 9324147 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding (FEED) starting on postoperative day (POD) 1 via a jejunostomy tube, n = 12
Number of subjects: 29
Study 9324147 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluid (IVF), n = 17
Number of subjects: 29
Study 8463437 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 19
Study 8463437 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 19
Study 2412521 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate (N=5)
Number of subjects: 14